Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

by palligoelme@gmail.com | Aug 5, 2026 | Clinical Trials

​ Conditions: Uterine Endometrial Cancer Interventions: Drug: TUB-040 – Dose escalation; Drug: TUB-040 – RP2D Sponsors: Tubulis GmbH Not yet recruiting Conditions: Uterine Endometrial Cancer Interventions: Drug: TUB-040 – Dose escalation; Drug:...

Improving Parent Sign-Up for a Children’s Stroke Awareness Program

by palligoelme@gmail.com | Aug 5, 2026 | Clinical Trials

​ Conditions: Stroke; Health Knowledge, Attitudes, Practice Interventions: Behavioral: Printed Letter; Behavioral: E-mail Invitation; Behavioral: E-mail Invitation Plus Teacher Feedback; Behavioral: Email Invitation Plus Teacher Feedback Plus Automated Chatbot...

[Trial of device that is not approved or cleared by the U.S. FDA]

by palligoelme@gmail.com | Aug 5, 2026 | Clinical Trials

​ Sponsors: [Redacted] Withheld Sponsors: [Redacted] Withheld 

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

by palligoelme@gmail.com | Aug 5, 2026 | Clinical Trials

​ Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma; Relapsed/Refractory Mantle Cell Lymphoma Interventions: Biological: Glofitamab Sponsors: Joshua Brody; Genentech, Inc. Not yet recruiting Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma;...

The Reliability and Validity of Little’s Irregularity Index Assessment

by palligoelme@gmail.com | Aug 5, 2026 | Clinical Trials

​ Conditions: Dental Crowding; Malocclusion, Angle Class I Sponsors: Al-Azhar University Completed Conditions: Dental Crowding; Malocclusion, Angle Class I Sponsors: Al-Azhar University Completed